Sazonov D V, Babenko L A, Yarmoschuk A V, Didrikh E M
'Siberian District Medical Center of the Federal Medical and Biological Agency' of Russia, Novosibirsk, Russia.
Medical center 'Avicenna' group of companies 'Mother and Child', Novosibirsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(12):25-30. doi: 10.17116/jnevro201811812125.
To perform a comparative study of the results of optical coherence tomography of the retina in patients with relapsing-remitting multiple sclerosis, treated with glatiramer acetate (timexon).
The study included 19 patients (16 women and 3 men) with relapsing-remitting multiple sclerosis who were treated with the glatiramer acetate generic drug timexon (BIOCAD, Russia). Dynamic changes in the main parameters of the optical coherence tomography linked with neurodegeneration manifestations in the retina during the year of the study were evaluated.
The efficacy of timexon in the progression of neurodegenerative changes in the retina was shown.
对接受醋酸格拉替雷（替罗非班）治疗的复发缓解型多发性硬化症患者的视网膜光学相干断层扫描结果进行比较研究。
该研究纳入了19例复发缓解型多发性硬化症患者（16名女性和3名男性），他们接受了醋酸格拉替雷仿制药替罗非班（俄罗斯BIOCAD公司生产）的治疗。评估了在研究的一年中，与视网膜神经变性表现相关的光学相干断层扫描主要参数的动态变化。
显示了替罗非班在视网膜神经退行性变进展方面的疗效。
